The Federal Trade Commission on Tuesday released an interim report saying that powerful drug middlemen marked up drugs for ...

Mattingly is an associate professor and vice chair of research in the Department of Pharmacotherapy at the University of Utah ...

The Pharmaceutical Care Management Association, which represents PBM's, called the FTC report baseless and "without ...

"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...

Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...

The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...

The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...

Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in revenue from marking up the prices of dozens of specialty generic drugs ...

CVS Caremark Rx blasted the findings for cherry picking certain drugs in an effort to push what it called an 'anti-PBM' ...

CVS Caremark, Express Scripts and OptumRx dramatically mark up specialty generic drugs to affiliated pharmacies, the Federal ...

The pharmaceutical supply chain is a sector infamous for glacially slow adjustments, lackluster reform, lack of transparency ...

UnitedHealth shares a quarterly report for the first time since the death of insurance unit leader Brian Thompson. A look at ...